Table 2.
Antimicrobial group | 2010 |
2011 |
2012 |
2013 |
2014 |
2015 |
2016 |
---|---|---|---|---|---|---|---|
DDD (×1,000) | |||||||
Antibacterials for systemic use (J01) | 5983.4 | 6130.4 | 6218.2 | 6455.0 | 6420.1 | 6597.8 | 6652.8 |
Antiprotozoals (P01AB) | 43.2 | 45.4 | 47.8 | 50.9 | 54.6 | 58.9 | 59.3 |
Antimicrobial product | DID | ||||||
---|---|---|---|---|---|---|---|
Amoxicillin (J01CA04) | 0.702 | 0.717 | 0.732 | 0.762 | 0.770 | 0.792 | 0.789 |
Amoxicillin + enzyme inhibitor (J01CR02) | 0.561 | 0.570 | 0.565 | 0.595 | 0.587 | 0.609 | 0.620 |
Ratio J01CA04/J01CR02* | 1.251 | 1.258 | 1.296 | 1.281 | 1.312 | 1.300 | 1.273 |
Clindamycin (J01FF01) | 0.074 | 0.074 | 0.078 | 0.079 | 0.076 | 0.076 | 0.075 |
Clarithromycin (J01FA09) | 0.058 | 0.055 | 0.049 | 0.045 | 0.043 | 0.040 | 0.039 |
Doxycycline (J01AA02) | 0.050 | 0.049 | 0.045 | 0.042 | 0.036 | 0.034 | 0.031 |
Azithromycin (J01FA10) | 0.025 | 0.024 | 0.025 | 0.025 | 0.025 | 0.026 | 0.027 |
Metronidazole (P01AB01) | 0.011 | 0.011 | 0.012 | 0.012 | 0.013 | 0.014 | 0.014 |
Spiramycin (J01FA02) | 0.009 | 0.008 | 0.007 | 0.007 | 0.006 | 0.006 | 0.005 |
Cefuroxime (J01DC02) | 0.005 | 0.005 | 0.005 | 0.005 | 0.006 | 0.005 | 0.005 |
Nitrofurantoin (J01XE01) | 0.002 | 0.002 | 0.003 | 0.003 | 0.003 | 0.003 | 0.003 |
Phenoxymethylpenicillin (J01CE02) | <0.0001 | 0.0001 | 0.0001 | 0.0001 | 0.0001 | 0.0001 | 0.0001 |
Other | 0.026 | 0.023 | 0.022 | 0.022 | 0.021 | 0.017 | 0.013 |
Antibacterials for systemic use (J01) | 1.512 | 1.527 | 1.531 | 1.584 | 1.573 | 1.609 | 1.607 |
Antiprotozoals (P01AB) | 0.011 | 0.011 | 0.012 | 0.013 | 0.013 | 0.014 | 0.014 |
Total | 1.523 | 1.538 | 1.543 | 1.597 | 1.586 | 1.623 | 1.621 |
Antimicrobial group | DDD/Prescriber | ||||||
---|---|---|---|---|---|---|---|
Antibacterials for systemic use (J01) | 852 | 868 | 867 | 893 | 872 | 875 | 869 |
Antiprotozoals (P01AB) | 6.2 | 6.4 | 6.7 | 7.0 | 7.4 | 7.8 | 7.7 |
Calculated as DID(J01CA04) divided by DID(J01CR02).
DDD, defined daily dose; DID, DDDs per 1,000 inhabitants per day.